WHO ICTRP trial

SFX-01 treatment for Acute Respiratory Infections (STAR-Covid19)

EUCTR2020-003486-19-GB · EU Clinical Trials Register · Authorised

Key facts

Trial ID EUCTR2020-003486-19-GB
Public title SFX-01 treatment for Acute Respiratory Infections (STAR-Covid19)
Scientific title A randomised, double-blind, placebo-controlled trial of SFX-01 or placebo on a backbone of best standard care, to improve outcomes in patients with community acquired pneumonia and suspected or confirmed SARS-CoV-2 infection - SFX-01 treatment for Acute Respiratory Infections (STAR-Covid19)
Primary sponsor University of Dundee
Registry EU Clinical Trials Register
Recruitment status Authorised
Study type Interventional clinical trial of medicinal product
Phase Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no
Countries United Kingdom
Conditions Community acquired pneumonia with suspected or confirmed SARS-CoV-2 infection MedDRA version: 20.1 Level: LLT Classification code 10066724 Term: Acute pneumonia System Organ Class: 10021881 - Infections and infestations MedDRA version: 20.1…
Interventions Product Name: Sulforadex Product Code: SFX-01 Pharmaceutical Form: Capsule, hard INN or Proposed INN: Sulforadex CAS Number: 1039704-32-9 Current Sponsor code: SFX-01 Other descriptive name: Sulforaphane/a-Cyclodextrin complex Concentration…
Registration date Aug 14, 2020
Target size 300
Secondary IDs 1.002.20
Registry page clinicaltrialsregister.eu

At a glance

  • No Results available

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About WHO ICTRP trial registrations

The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.

Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date:

Browse all WHO ICTRP trial registrations